Lung Cancer Screening Market to Grow Significantly by 2035
Global, Thursday, 16 January 2025.
The lung cancer screening market is expected to expand from USD 3.61 billion in 2024 to USD 9.50 billion by 2035, driven by technological advancements and increasing screening programs.
Market Growth Dynamics
The global lung cancer screening market is poised for substantial growth, with a projected compound annual growth rate (CAGR) of 9.18% from 2025 to 2035 [1]. This remarkable expansion is being fueled by several key factors, including rising lung cancer incidence rates and increased government initiatives for early detection programs [1]. North America currently dominates the market, primarily due to its robust healthcare infrastructure and favorable reimbursement policies [1][3]. Meanwhile, the Asia Pacific region is emerging as the fastest-growing market segment [1], with significant developments such as Project HOPE’s lung cancer care program launched in Yunnan Province, China in May 2024 [1].
Technological Innovations Driving Prevention
The market is witnessing significant technological breakthroughs in screening methodologies. The low-dose spiral CT scan segment currently leads revenue generation [1], while innovative developments like nanoparticle sensors for lung cancer detection, developed by MIT in January 2024, are advancing the field [1]. These advancements are complemented by the emergence of AI-powered solutions, which are increasingly being integrated into healthcare systems to improve diagnostic accuracy and efficiency [7]. The non-small cell lung cancer (NSCLC) segment currently holds the highest revenue share [1], reflecting the market’s response to the most common form of lung cancer.
Integration with Immunotherapy Advances
The lung cancer screening market’s growth is further supported by parallel developments in cancer immunotherapy, which is projected to reach US$236.9 billion by 2030 [3]. The lung cancer application segment maintains the largest market share at 13.8% [3], highlighting the critical importance of early detection and treatment. This integration of screening and treatment approaches is creating a more comprehensive cancer care ecosystem, with hospitals and clinics dominating the end-user market with a 49.8% share [3].
Future Outlook and Implementation
Looking ahead, the market is expected to benefit from increasing healthcare investments and expanding screening programs. Recent initiatives, such as Nova Scotia’s new cancer screening program launched in January 2024 [1], demonstrate growing institutional commitment to early detection. The implementation of value-based care models, with 90 million patients projected to enroll in such systems by 2027 [6], is expected to further support market growth. Healthcare organizations are being advised to evaluate their screening protocols and invest in technology to capitalize on these emerging opportunities [6].